Cargando…

Dual targeting of the tumor and its associated vasculature using a single bispecific chimeric antigen receptor molecule

Detalles Bibliográficos
Autores principales:	Byrd, Tiara, Fousek, Kristen, Pignata, Antonella, Wakefield, Amanda, Grada, Zakaria, Aviles-Padilla, Kevin, Fletcher, Bradley S, Hegde, Meenakshi, St Croix, Brad, Ahmed, Nabil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288703/ http://dx.doi.org/10.1186/2051-1426-2-S3-P6

Ejemplares similares

TEM8 specific T cells target the tumor cells and tumor-associated vasculature in triple negative breast cancer
por: Byrd, Tiara, et al.
Publicado: (2014)

A bispecific chimeric antigen receptor molecule enhances T cell activation through dual immunological synapse formation and offsets antigen escape in glioblastoma
por: Hegde, Meenakshi, et al.
Publicado: (2015)

TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
por: Grada, Zakaria, et al.
Publicado: (2013)

Polystyrene microspheres enable 10‐color compensation for immunophenotyping of primary human leukocytes
por: Byrd, Tiara, et al.
Publicado: (2015)

Chimeric Humanized Vasculature and Blood: The Intersection of Science and Ethics
por: Garry, Daniel J., et al.
Publicado: (2020)

A Homing System Targets Therapeutic T-cells to Brain Cancer
por: Samaha, Heba, et al.
Publicado: (2018)

Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update
por: Alsajjan, Roa, et al.
Publicado: (2023)

Bispecific Chimeric Antigen Receptor T Cell Therapy for B Cell Malignancies and Multiple Myeloma
por: Cronk, Robert J., et al.
Publicado: (2020)

Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody
por: Park, Jeong A, et al.
Publicado: (2023)

Targeting the vasculature in cardiometabolic disease
por: Boutagy, Nabil E., et al.
Publicado: (2022)

Is CMV a target in pediatric glioblastoma? Expression of CMV proteins, pp65 and IE1-72 and CMV nucleic acids in a cohort of pediatric glioblastoma patients
por: Wakefield, Amanda, et al.
Publicado: (2015)

Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells
por: Strohl, William R., et al.
Publicado: (2019)

Chimeric Antigen Receptor–Modified T Cells and T Cell–Engaging Bispecific Antibodies: Different Tools for the Same Job
por: Schwerdtfeger, Melanie, et al.
Publicado: (2021)

Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
por: Alqazaqi, Raghad, et al.
Publicado: (2022)

Enhancing the effectiveness of γδ T cells by mRNA transfection of chimeric antigen receptors or bispecific T cell engagers
por: Becker, Scott A., et al.
Publicado: (2023)

Enhancing the effectiveness of γδ T cells by mRNA transfection of chimeric antigen receptors or bispecific T cell engagers
por: Anderson, John, et al.
Publicado: (2023)

CD19/CD22 bispecific chimeric antigen receptor‑NK‑92 cells are developed and evaluated
por: Kim, Hyori, et al.
Publicado: (2023)

Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial.
por: Ahmed, Nabil, et al.
Publicado: (2015)

A chimeric antigen receptor against prostate-specific membrane antigen, a tumor vasculature target
por: Santoro, Stephen P, et al.
Publicado: (2013)

A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs)
por: Stone, Jennifer D., et al.
Publicado: (2012)

Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2
por: Hoseini, Sayed Shahabuddin, et al.
Publicado: (2017)

Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management
por: Markouli, Mariam, et al.
Publicado: (2023)

Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function
por: Leung, Isabel, et al.
Publicado: (2022)

Improving VEGF-targeted therapies through inhibition of COX-2/PGE(2) signaling
por: Xu, Lihong, et al.
Publicado: (2014)

CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression
por: Fousek, Kristen, et al.
Publicado: (2020)

Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma.
por: Luiten, R. M., et al.
Publicado: (1996)

Serum albumin binding knob domains engineered within a V(H) framework III bispecific antibody format and as chimeric peptides
por: Adams, Ralph, et al.
Publicado: (2023)

Tumour vasculature--a potential therapeutic target.
por: Baillie, C. T., et al.
Publicado: (1995)

Theranostics in the vasculature: bioeffects of ultrasound and microbubbles to induce vascular shutdown
por: Padilla, Frederic, et al.
Publicado: (2023)

Endocrinology of the vasculature
Publicado: (1996)

Interaction Between Blood Vasculatures and Lymphatic Vasculatures During Inflammation
por: Wang, Shun-Shun, et al.
Publicado: (2023)

Bispecific antibodies and their applications
por: Fan, Gaowei, et al.
Publicado: (2015)

The making of bispecific antibodies
por: Brinkmann, Ulrich, et al.
Publicado: (2017)

Successful treatment of relapsed acute B-cell lymphoblastic leukemia with CD20/CD22 bispecific chimeric antigen receptor T-cell therapy
por: Liang, Zuyu, et al.
Publicado: (2020)

Chemoprevention of metastasis
por: Emenaker, Nancy J., et al.
Publicado: (2014)

Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes
por: Liu, Jie, et al.
Publicado: (2021)

Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors
por: Hambach, Julia, et al.
Publicado: (2022)

BEAT(® )the bispecific challenge: a novel and efficient platform for the expression of bispecific IgGs
por: Moretti, Pierre, et al.
Publicado: (2013)

Prognostic implications of peritumoral vasculature in head and neck cancer
por: Evans, Michael, et al.
Publicado: (2018)

Homogeneous Bispecifics by Disulfide Bridging
por: Hull, Elizabeth A., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_3d6oua85k78o5pm9uu2p22nm4k